Anti-Mouse CTLA-4 Antibody (9D9)

Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8 + T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma ^{[1] [2]}.

In Vivo, Anti-Mouse CTLA-4 Antibody (9D9) (200 μg, i.p. or i.t., on day 7, 10 and 14) has significant anti-tumor activity and increases CD4+/CD8+ T cell activation in female C57BL/6 mice bearing MC38 tumors^[1]. Anti-Mouse CTLA-4 Antibody (9D9) (100 μg/dose, i.p., on day 3, 6 and 9) has significant anti-tumor activity and prolongs survival in male C57BL/6 mice bearing B16-F10 tumors^[2].

In Vitro, Anti-Mouse CTLA-4 Antibody (9D9) (0.1-1000 nM, 2 h) has high binding strength with CTLA-4WT (KD = 15.4 nM) and CTLA-4del36 (KD = 69.6 nM) in HEK293-F cells^[1]. Anti-Mouse CTLA-4 Antibody (9D9) (0.01-1000 nM, 1 h) significantly blocks the binding of B7 to CTLA-4 in HEK293-F cells (IC₅₀ = 23.5 nM for ELISA, IC₅₀ = 24.4 nM for cell surface)^[1].

References:
[1]. Lax BM, et al. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Proc Natl Acad Sci U S A. 2023 Aug;120(31):e2300895120.
[2]. Reilley MJ, et al. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. J Immunother Cancer. 2019 Nov 26;7(1):323.